Bruker Corporation (NASDAQ:BRKR) reported preliminary revenue Friday for the first quarter that ended March 31, 2025, of $795 million to $800 million compared to a consensus of $758.85 million.
The company’s sales reflect around 10-11% year-over-year increase from $721.70 million.
Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research and industrial and applied analysis.
This estimated range implies a reported revenue growth of approximately 10% year over year, with low double-digit percentage constant exchange rate revenue growth.
Bruker estimates adjusted organic revenue growth in the first quarter to be in the low single-digit percentages, with mid-single-digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment and a high-teens percentage organic revenue decline in the Bruker Energy & Supercon Technologies (BEST) segment, net of intercompany eliminations.
Concurrently, at the ESCMID Global 2025 conference, Bruker’s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use-only NGS-based solutions in epidemiology and hospital-acquired infection (HAI) tracing.
On Friday, Bruker entered into a strategic collaboration with Ridom GmbH, based in Muenster, Germany, for NGS bioinformatics applications in microbiology and infectious disease testing.
Ridom’s NGS bioinformatics software SeqSphere+ is designed for genomic bacterial strain differentiation, multilocus sequence typing (MLST), core genome MLST (cgMLST), phylogenetic analysis, and real-time clonal and plasmid transmission detection.
SeqSphere+ can handle data from various NGS instrument platforms. Financial details of the investment were not disclosed.
In October 2024, Bruker acquired Dynamic Biosensors GmbH, a biosensor development company based in Munich, Germany.
The acquisition strengthened Bruker’s biophysical portfolio for analyzing molecular interactions and kinetics.
Price Action: BRKR’s stock was up 2.47% at $39.01 during the premarket session on Friday.
Read Next:
Photo: Shutterstock
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。